Does Medicaid cover Mounjaro in Illinois?

If you’re exploring GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight management, you’re likely wondering: Will my insurance cover this? The answer isn’t straightforward—and it’s changing rapidly in 2025.

With monthly costs exceeding $1,000 without insurance and new manufacturer programs slashing self-pay prices, understanding your coverage options has never been more important. This comprehensive guide breaks down exactly what commercial insurance, Medicare, and Medicaid cover, what prior authorization hurdles you might face, and how to access these medications affordably whether you have coverage or not.

Understanding GLP-1 Medications: What’s the Difference?

Before diving into insurance coverage, it’s essential to understand what these medications are approved to treat—because that determines whether insurance will pay.

Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. It’s also approved for reducing cardiovascular risk in adults with obesity and established heart disease.

Ozempic (also semaglutide) is FDA-approved only for Type 2 diabetes management. While it causes weight loss as a side effect, using it solely for weight management is considered off-label.

Mounjaro (tirzepatide) is approved for Type 2 diabetes. Its sister medication, Zepbound (same active ingredient), is approved for weight management—but many people seek Mounjaro off-label for weight loss.

This distinction matters enormously for insurance coverage. Most plans readily cover diabetes medications but heavily restrict or exclude weight-loss drugs entirely.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: A Complex Landscape

Does Private Insurance Cover These Medications?

The short answer: It depends entirely on your specific plan—and whether you’re seeking treatment for diabetes or weight loss.

For diabetes treatment, commercial insurers generally cover Ozempic and Mounjaro as essential health benefits. Coverage typically includes:

• Placement on formulary (usually Tier 3, sometimes Tier 4 specialty)
• Prior authorization requirements to confirm Type 2 diabetes diagnosis
• Step therapy protocols requiring you to try metformin or other first-line diabetes medications first
• Copays ranging from $25 to several hundred dollars depending on your plan’s structure

For weight loss treatment, the picture is dramatically different. Many employer-sponsored plans explicitly exclude obesity drugs as optional benefits due to cost concerns. According to recent surveys, roughly half of large employers do not cover GLP-1 medications for weight management at all.

When coverage exists for Wegovy, insurers impose strict gatekeeping:

• BMI requirements: Usually ≥30, or ≥27 with at least one weight-related comorbidity (hypertension, Type 2 diabetes, dyslipidemia, or obstructive sleep apnea)
• Documented lifestyle intervention: Evidence of at least six months of supervised diet and exercise programs
• Prior medication trials: Some plans require trying older, cheaper weight-loss medications first
• Ongoing monitoring: Approval often limited to 3-6 months initially, requiring documented weight loss (typically ≥5%) for renewal

Common Prior Authorization Criteria

Let’s look at what a typical commercial insurer requires. Aetna’s May 2024 policy bulletin outlines specific criteria that mirror most major insurers:

• Patient age 18 or older
• BMI ≥35, or BMI 30-34.9 with at least one obesity-related comorbidity
• Documentation of at least six months of physician-supervised dietary and exercise program
• No contraindications (pregnancy, personal or family history of medullary thyroid carcinoma, etc.)
• Prescriber must be an endocrinologist, obesity medicine specialist, or physician with documented expertise

Quantity limits are standard—typically four pens per 28 days, aligned with the medication’s dosing schedule.

Why Do Insurers Deny Coverage?

Understanding common denial reasons helps you prepare a stronger initial request:

1. Insufficient BMI documentation: Your medical records must clearly show qualifying BMI measurements
2. Missing lifestyle intervention records: Insurers want proof you’ve tried diet and exercise under medical supervision for the required timeframe
3. Off-label use: Requesting Ozempic for weight loss when you don’t have diabetes triggers automatic denials
4. Plan exclusions: If your employer opted out of obesity drug coverage, no amount of documentation will help
5. Incomplete prior authorization paperwork: Missing clinical notes, lab values, or comorbidity documentation

Medicare Coverage: Limited and Specific

Medicare Part D does not cover medications prescribed solely for weight loss. This exclusion is written into federal law under the Social Security Act.

However, there’s an important exception: Medicare will cover Wegovy when prescribed for FDA-approved uses beyond weight management. As of March 2024, CMS approved coverage for Wegovy to reduce cardiovascular risk in adults with obesity and established cardiovascular disease. This means if you have:

• Obesity (BMI ≥27)
• AND documented cardiovascular disease (prior heart attack, stroke, or coronary artery disease)

Your Medicare Part D plan may cover Wegovy for cardiovascular risk reduction—not for weight loss per se.

For diabetes management, Medicare covers Ozempic and Mounjaro on Part D formularies, typically requiring prior authorization to confirm diagnosis and appropriate use. These medications are usually placed on specialty tiers with higher cost-sharing.

Medicare Advantage plans began offering limited obesity drug coverage in 2025, but this varies by plan and comes with strict utilization management.

Medicaid Coverage: State-by-State Variation

Medicaid coverage for weight-loss medications is perhaps the most complex and rapidly changing landscape. States have the option to cover anti-obesity drugs, but most choose not to due to budget constraints.

Current State Coverage Overview

As of December 2025, approximately 13 states offer some Medicaid coverage for GLP-1 weight-loss medications—and that number is shrinking. Here’s what’s happening in key states:

California covered Wegovy with prior authorization through 2025, but all coverage ends January 1, 2026 as a budget-cutting measure. After this date, adult Medi-Cal beneficiaries will have no coverage for weight-loss medications, though pediatric patients may access them through EPSDT (Early and Periodic Screening, Diagnostic and Treatment) provisions.

Pennsylvania added Wegovy coverage in 2023 with strict criteria, but announced it will discontinue coverage in January 2026 due to cost pressures, following California’s lead.

Texas never covered obesity medications for adults aged 21 and older. The Texas Vendor Drug Program explicitly excludes Wegovy, Saxenda, and similar drugs. Patients under 21 can request case-by-case exceptions through EPSDT.

Florida similarly does not cover weight-loss drugs, exercising the optional exclusion available under federal Medicaid rules.

New York continues to cover Wegovy through its NYRx formulary with prior authorization, requiring documented BMI ≥30 (or ≥27 with comorbidities), lifestyle modification attempts, and age ≥18. Quantity limits of four pens per 28 days apply.

Why States Are Cutting Coverage

The dramatic rollback in state Medicaid coverage stems directly from cost. GLP-1 medications for obesity represent one of the fastest-growing categories of Medicaid spending. With list prices around $1,350 monthly for Wegovy, widespread coverage would cost state budgets hundreds of millions—potentially billions—annually.

States that do maintain coverage impose rigorous utilization management:

• Mandatory prior authorization reviewing BMI, comorbidities, and prior interventions
• Step therapy requirements (trying older weight-loss medications first)
• Quantity limits aligned with FDA dosing
• Periodic re-evaluation (often every 3-6 months) requiring documented weight loss to continue coverage

For diabetes indications, Medicaid programs universally cover Ozempic and Mounjaro with prior authorization to confirm diagnosis, making diabetes treatment access considerably better than obesity treatment access.

Navigating Prior Authorization: A Step-by-Step Guide

Whether you have commercial insurance or Medicaid coverage, prior authorization is almost inevitable for GLP-1 medications. Here’s how to increase your approval chances:

1. Document Everything Before You Apply

Work with your healthcare provider to compile:

• Current BMI measurements from multiple recent visits
• Comprehensive weight history showing obesity duration
• Documentation of weight-related comorbidities with diagnosis codes (Type 2 diabetes, hypertension, dyslipidemia, sleep apnea, etc.)
• Records of supervised lifestyle interventions: dietitian visits, exercise program participation, behavioral counseling—spanning at least six months
• Previous weight-loss medication trials if applicable

2. Understand Your Plan’s Specific Requirements

Call your insurance company or check your formulary online for:

• Exact BMI thresholds required
• Duration of lifestyle intervention needed
• Whether step therapy (trying other medications first) applies
• Specialty requirements for prescribing provider
• Any diagnosis code restrictions

3. Have Your Provider Submit a Comprehensive Letter of Medical Necessity

A strong letter includes:

• Clear statement of diagnosis (obesity with specific ICD-10 codes)
• Detailed medical history and comorbidities
• Summary of previous weight-loss attempts and outcomes
• Clinical rationale for GLP-1 therapy specifically
• Discussion of potential health risks if obesity remains untreated
• Reference to clinical guidelines supporting treatment

4. Follow Up Actively

Prior authorization responses typically come within 5-7 business days for urgent requests, up to 14 days for standard reviews. If denied:

• Request a detailed written explanation
• Identify exactly which criteria weren’t met
• Gather additional documentation to address gaps
• File a formal appeal within the timeframe specified (usually 60-180 days)

5. Consider Peer-to-Peer Review

Many insurance companies allow your prescribing physician to speak directly with the plan’s medical director. These peer-to-peer conversations can clarify clinical necessity and sometimes overturn denials when documentation alone doesn’t suffice.

When Insurance Won’t Cover: Self-Pay Options

If your insurance doesn’t cover these medications—or you’re uninsured—don’t lose hope. Major pricing changes in late 2025 have made self-pay options significantly more affordable.

Manufacturer Programs

Novo Nordisk (Wegovy and Ozempic) launched reduced self-pay pricing in November 2025:

• Wegovy: $349 per month through participating retail pharmacies (down from list price of ~$1,350)
• Ozempic: Lower doses starting at $349/month; higher doses around $499/month
• NovoCare savings cards for commercially insured patients can reduce copays to as little as $0-$25 monthly (maximum savings up to $225 per fill)

Eli Lilly (Mounjaro/Zepbound) offers:

• Single-dose vials through LillyDirect starting at $299-$449 monthly depending on dose
• Savings cards for Type 2 diabetes patients with commercial insurance: typically $25 per month
• Patient assistance programs for uninsured individuals meeting income criteria

GoodRx Partnership Pricing

In a groundbreaking move, GoodRx partnered with Novo Nordisk to offer unprecedented pricing:

• $199 per month for the first two fills of Wegovy or Ozempic
• $349 per month ongoing for most doses
• Available at nearly all pharmacies nationwide with a GoodRx coupon
• No insurance required; available to cash-pay patients

This represents approximately 70% savings off typical retail prices and makes these medications accessible to many who previously couldn’t afford them.

Patient Assistance Programs

Both Novo Nordisk and Eli Lilly maintain robust patient assistance programs (PAPs) for qualifying low-income, uninsured patients:

• Typically require household income below 400% of federal poverty level
• Provide medications at no cost for approved applicants
• Require annual reapplication with financial documentation
• Application process takes 2-4 weeks through providers or patient assistance foundations

Comparing Costs: Insurance vs. Self-Pay

Let’s look at a realistic scenario:

With insurance approval:

• Tier 3 copay: $50-$150/month
• Tier 4 specialty copay: $150-$400/month
• High-deductible plans: Full cost until deductible met (potentially $1,000+), then coinsurance

Self-pay options:

• List price: $998-$1,350/month
• GoodRx partnership: $199 initial, then $349/month
• Manufacturer cash programs: $299-$499/month
• With savings card (if insured): $0-$25/month

For some patients, manufacturer savings cards combined with insurance actually cost less than high-deductible plan out-of-pocket maximums. Always compare all options.

Telehealth Access: Insurance Coverage for Virtual Visits

Good news: telehealth has become mainstream for weight management and metabolic health. Over 40 states now have insurance parity laws requiring private insurers to cover telehealth services equivalently to in-person visits.

What this means for you:

• Most commercial plans cover telehealth consultations for obesity treatment, nutritional counseling, and medication management at the same rate as office visits
• Medicare expanded telehealth coverage during the pandemic and has maintained many flexibilities, including coverage for weight management counseling
• Medicaid coverage varies by state but generally includes telehealth for chronic disease management

Important considerations:

• Confirm your telehealth provider is in-network with your insurance
• Some plans require live video (not just phone or asynchronous messaging)
• Nutritional counseling for obesity is an ACA-mandated preventive service and must be covered by commercial plans
• Even if the telehealth visit is covered, medication prior authorization still applies separately

Platforms like Klarity Health offer a unique advantage here: with providers available across multiple states, flexible appointment scheduling, and transparent pricing whether you’re using insurance or paying cash, you can access expert weight management care without the typical barriers of months-long wait times or geographic limitations. For patients whose insurance won’t cover GLP-1 prescriptions but will cover the medical visits, this creates a practical pathway to care.

Strategic Approaches to Getting Coverage Approved

Based on successful appeals and prior authorization approvals, here are proven strategies:

For Commercial Insurance

1. Frame obesity as a chronic disease with medical consequences: Emphasize comorbidities and their associated costs. Insurers respond to data showing GLP-1s reduce cardiovascular events, diabetes progression, and other expensive complications.

2. Provide robust lifestyle intervention documentation: Six months of supervised diet and exercise is standard. Work with a registered dietitian or weight management program that provides detailed visit records.

3. Get specialist involvement early: Prescriptions from endocrinologists or obesity medicine specialists often face less scrutiny than those from primary care providers (though this shouldn’t be required).

4. Use clinical guidelines as evidence: Reference the American Diabetes Association, American Association of Clinical Endocrinologists, and other professional society guidelines supporting GLP-1 use.

5. Emphasize failed prior attempts: Documentation of inadequate response to other weight-loss interventions strengthens medical necessity.

For Medicaid (Where Available)

1. Verify current coverage status: State Medicaid formularies change frequently. Check your state’s Department of Health Services or Medicaid pharmacy program website.

2. Understand EPSDT provisions: If you’re under 21, you have broader coverage rights. EPSDT requires states to cover medically necessary treatments for children even if not typically covered for adults.

3. Document severe health risks: States are more likely to approve coverage when obesity is causing immediate health crises or high-cost complications.

4. Consider dual-eligibility rules: If you have both Medicare and Medicaid, Medicaid may cover obesity drugs that Medicare won’t (though this loophole is closing as states cut coverage).

If Initially Denied

File an appeal immediately. Insurance denial letters include appeal instructions and deadlines—typically 60-180 days. Your appeal should:

• Address every reason for denial specifically
• Provide additional documentation filling any gaps
• Include updated clinical information if your health has changed
• Request an expedited review if medically urgent

Consider external review: If internal appeals fail, most states allow external review by independent medical experts. These overturn denials in 30-40% of cases when clinical evidence supports treatment.

Contact your state insurance commissioner: For commercial plans, state insurance departments can intervene in coverage disputes, particularly if you can show the plan violated its own policies or state laws.

Understanding the Bigger Picture: Why Coverage Is So Restrictive

The insurance industry’s caution around covering obesity medications stems from several factors:

Cost concerns top the list. With an estimated 42% of U.S. adults having obesity, universal coverage of $1,000+ monthly medications would add tens of billions to healthcare spending annually. Insurers—and the employers who fund most commercial plans—fear unsustainable budget impacts.

Lack of long-term data on medication persistence raises questions. Do patients stay on these medications indefinitely? What happens when they stop? Insurers worry about covering expensive medications if weight returns after discontinuation, making the investment temporary.

Alternative interventions exist, from lifestyle modification programs to bariatric surgery (which insurance often covers for severe obesity). Insurers argue these should be tried first.

Off-label use concerns are significant. The explosion of demand for GLP-1s for cosmetic weight loss in people without medical obesity has made insurers hypervigilant about inappropriate use.

However, the landscape is evolving. As clinical evidence mounts showing cardiovascular benefits, diabetes prevention, and potential impacts on other conditions (sleep apnea, fatty liver disease, arthritis), the cost-benefit equation changes. The FDA’s 2024 approval of Wegovy for cardiovascular risk reduction—and Medicare’s subsequent coverage decision—signals shifting perspectives.

What to Know Before Starting Treatment

Whether paying out-of-pocket or using insurance, understand what you’re committing to:

Treatment Duration

GLP-1 medications for weight management typically require indefinite use. Most patients regain weight within months of stopping. This isn’t a short-term solution—it’s chronic disease management similar to blood pressure or cholesterol medications.

Insurance implications: Some plans only approve initial 3-6 month trials, requiring documented weight loss for continuation. Plan for ongoing prior authorization battles.

Cost implications: At $300-$1,300+ monthly, calculate annual costs. Even with insurance, specialty tier copays can exceed $2,000-$4,000 yearly.

Side Effects and Monitoring

Common GI side effects (nausea, diarrhea, constipation) affect most patients initially. Rare but serious risks include pancreatitis, gallbladder disease, and thyroid tumors (in animal studies).

Regular monitoring includes:

• Baseline and periodic thyroid function tests
• Lipase levels if symptoms suggest pancreatitis
• Assessment of heart rate (can increase on GLP-1s)
• Nutritional status and vitamin levels

Insurance note: Some plans require documented tolerance of lower doses before approving higher doses—another utilization management strategy.

Lifestyle Integration

No medication replaces healthy eating and physical activity. Insurance companies requiring lifestyle intervention aren’t wrong—these medications work best alongside behavior change. Success stories involve:

• Working with registered dietitians on sustainable nutrition changes
• Gradually increasing physical activity as weight decreases
• Addressing psychological factors through counseling
• Building support systems for long-term adherence

Practical Next Steps: Your Action Plan

If you have commercial insurance:

1. Call your insurer’s member services line and ask specifically about coverage for Wegovy, Ozempic (if diabetic), or Mounjaro (if diabetic)
2. Request prior authorization requirements in writing
3. Schedule an appointment with your provider to discuss treatment and begin documenting qualifying criteria
4. If coverage exists, ensure you meet all criteria before your provider submits PA
5. If denied, immediately file an appeal with additional documentation

If you have Medicare:

1. Ask your provider whether you qualify for Wegovy under cardiovascular risk reduction indication (requires documented CVD plus obesity)
2. For diabetes medications (Ozempic/Mounjaro), verify your Part D plan’s formulary placement and requirements
3. Consider Medicare Advantage plans during open enrollment if your current plan doesn’t offer coverage you need

If you have Medicaid:

1. Check your state’s current formulary—coverage is changing rapidly in 2025-2026
2. Understand that even states with coverage have strict PA requirements
3. If under 21, ask about EPSDT coverage provisions
4. Be prepared for possible coverage termination as states cut obesity drug benefits

If uninsured or insurance won’t cover:

1. Explore manufacturer savings programs first (NovoCare, LillyDirect)
2. Sign up for GoodRx and compare their partnership pricing ($199-$349/month)
3. Apply for patient assistance programs if you meet income criteria
4. Consider telehealth platforms offering competitive cash-pay pricing
5. Ask about compounded versions only if prescribed by legitimate providers (understand FDA does not approve these formulations)

The Role of Klarity Health in Your Weight Management Journey

Finding a provider who understands both the clinical aspects of weight management and the insurance navigation process can be challenging. Klarity Health offers several advantages in this landscape:

• Provider availability across multiple states means you can access care regardless of where you live, with appointment times that work around your schedule—often within days rather than months
• Transparent pricing whether you’re using insurance or paying cash, so you know costs upfront
• Acceptance of both insurance and cash pay gives you flexibility if your plan doesn’t cover medications but will cover visits, or if you prefer self-pay for privacy
• Telehealth convenience eliminates geographic barriers and makes regular monitoring appointments realistic for busy patients

When you’re dealing with insurance denials, prior authorization paperwork, and the stress of managing a chronic condition, having a provider who’s equipped to help with the medical and logistical aspects of treatment matters. Whether you need a letter of medical necessity for appeal, documentation of lifestyle interventions, or simply prescribing flexibility based on your insurance situation, Klarity’s approach recognizes that healthcare navigation is part of comprehensive care.

Looking Ahead: The Future of GLP-1 Coverage

Several trends will shape coverage in coming years:

Medicare expansion is likely. Congressional proposals to allow Medicare coverage of obesity drugs are gaining bipartisan support. The 2026 election cycle may determine whether this becomes law.

Generic competition will eventually reduce costs. While no generics exist yet (patents extend into the 2030s), biosimilar versions will eventually drive prices down and expand coverage.

Outcomes data will influence policy. Long-term studies showing sustained health improvements, reduced cardiovascular events, and diabetes prevention will strengthen the case for coverage.

State Medicaid decisions remain fluid. Some states may restore coverage if federal subsidies increase or medication prices drop substantially. Others will maintain exclusions indefinitely.

Employer plan trends: Large self-insured employers are increasingly covering these medications with strict utilization management, finding that preventing diabetes and cardiovascular disease saves money long-term. This may gradually expand coverage.

Alternative delivery models: Monthly injection or longer-acting oral formulations in development could change cost dynamics and coverage decisions.

Final Thoughts

Navigating insurance coverage for GLP-1 weight-loss medications requires patience, persistence, and preparation. The system is complex, inconsistent across payers and states, and changing rapidly. But for many people struggling with obesity and related health conditions, these medications represent genuinely transformative treatment options worth the effort to access.

Key takeaways:

• Insurance coverage depends entirely on indication (diabetes vs. weight loss), payer type (commercial, Medicare, Medicaid), and specific plan details
• Prior authorization is nearly universal and requires thorough documentation of BMI, comorbidities, and prior interventions
• Self-pay options improved dramatically in late 2025, with prices as low as $199-$349 monthly through manufacturer programs and GoodRx
• Medicare covers these drugs for diabetes and specific cardiovascular indications, but generally not for weight loss alone
• Medicaid coverage is sparse and shrinking, with major states cutting benefits in 2026
• Denials can often be overturned with comprehensive appeals including strong clinical documentation
• Telehealth access is widely covered and removes geographic barriers to specialized weight management care

If you’re considering GLP-1 treatment, start by understanding your specific insurance situation, gathering documentation with your provider, and exploring both covered and self-pay pathways. Whether you end up with insurance coverage, manufacturer savings programs, or cash-pay options, these medications are increasingly accessible to those who can benefit from them.

Ready to explore your options? Consider connecting with providers who specialize in weight management and understand the insurance landscape, like the team at Klarity Health—where getting care shouldn’t be harder than the condition you’re treating.

Research Currency Statement

Verified as of December 17, 2025

Key Citations

1. Aetna Clinical Policy Bulletin – Weight Loss GLP-1 Agonists (May 2024). www.aetna.com

2. California Department of Health Care Services – Medi-Cal GLP-1 Coverage Termination Announcement (December 2025). www.cmadocs.org

3. KFF Issue Brief – Medicaid Coverage of and Spending on GLP-1s (November 2024). www.kff.org

4. GoodRx Press Release – New Weight Loss Telemedicine Subscription and Introductory Cash Pricing (November 17, 2025). www.businesswire.com

5. Fierce Pharma – Novo Nordisk and Eli Lilly Reduce Self-Pay Prices for GLP-1 Medications (November-December 2025). www.fiercepharma.com

Coverage policies and pricing change frequently. Always verify current information with your specific insurance plan and pharmacy before making treatment decisions.

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499